Results 361 to 370 of about 104,116 (405)
Some of the next articles are maybe not open access.
Clinical Pharmacology and Therapeutics, 1980
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone
Journal of Addiction Medicine, 2021Buprenorphine-naloxone (BNX) reduces the risk of mortality from untreated opioid use disorder by 50% or more. However, adverse effects of BNX can be a cause of inconsistent use or discontinuation. The buprenorphine monoproduct (BUP) is effective and is sometimes tolerated better, but practice guidelines and insurance ...
openaire +3 more sources
Journal of Opioid Management, 2018
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +3 more sources
A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
openaire +3 more sources
Journal of addiction medicine, 2021
Background Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine’s high-affinity blockade at mu-opioid receptors (μORs).
C. Hailozian +9 more
semanticscholar +1 more source
Background Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine’s high-affinity blockade at mu-opioid receptors (μORs).
C. Hailozian +9 more
semanticscholar +1 more source
Effect of buprenorphine on psychomotor functions in patients on buprenorphine maintenance
Journal of Opioid Management, 2018Objective: Patients on buprenorphine maintenance for opioid dependence often abuse its additional doses over and above the maintenance dose. Being a psychoactive agent, it may affect psychomotor performance with all its consequences, for example, effect on quality of life.
Raka Jain, MSc, PhD, Cchem, Frsc +4 more
openaire +3 more sources
Behavioral pharmacology of buprenorphine
Drug and Alcohol Dependence, 1985Buprenorphine is an opioid mixed agonist-antagonist that has potential usefulness as a pharmacotherapy for opiate addiction. Buprenorphine significantly suppressed opiate self-administration by heroin addicts. Buprenorphine also suppressed opiate self-administration in a primate model.
Nancy K. Mello, Jack H. Mendelson
openaire +3 more sources
Microinduction of Buprenorphine/Naloxone: A Review of the Literature.
American Journal on Addictions, 2020BACKGROUND AND OBJECTIVES Buprenorphine's high-binding affinity as a partial µ-opioid agonist displaces preexisting full agonists causing precipitated withdrawal, which requires most individuals starting buprenorphine to endure moderate withdrawal prior ...
Saeed Ahmed +3 more
semanticscholar +1 more source
Medical Journal of Australia, 1984
Buprenorphine is a powerful new analgesic agent with agonist and antagonist opiate receptor activity. Its withdrawal symptoms have been reported as being mild; however, its potential for abuse is not known. A case of buprenorphine abuse is reported, in which the patient's history and his response to naloxone suggest that important underlying factors ...
Allan J. Quigley +2 more
openaire +3 more sources
Buprenorphine is a powerful new analgesic agent with agonist and antagonist opiate receptor activity. Its withdrawal symptoms have been reported as being mild; however, its potential for abuse is not known. A case of buprenorphine abuse is reported, in which the patient's history and his response to naloxone suggest that important underlying factors ...
Allan J. Quigley +2 more
openaire +3 more sources
Enzyme immunoassay of buprenorphine
Naunyn-Schmiedeberg's Archives of Pharmacology, 1988Assays for the potent, highly lipophilic analgesic buprenorphine described in the literature include the radioimmunoassay (RIA), radioreceptor assay (RRA) and selected ion-monitoring. Problems arise with the use of hazardous and unstable ligand in the RIA and RRA and the need for an extraction step for RRA and selected ion-monitoring.
Jean E. Olley, George K. L. Tiong
openaire +3 more sources